Activ Surgical ActivSight vs C-SATS

Rating trainee video and imaging perfusion during an operation are separate purchases, and neither tool stands in for the other. C-SATS, a Johnson & Johnson product, sends recorded minimally invasive cases to expert surgeons and trained reviewers, and it sells on an enterprise basis at no public price. A residency director who wants repeatable ratings of trainee video buys it, and a department with no recording workflow has nothing to give it. Its method has a 2022 systematic review of 16 studies, 12 of them showing good or excellent agreement between crowd and expert ratings, and a 2025 Surgical Endoscopy paper asking whether it measures up. C-SATS states no FDA status. ActivSight is an intraoperative imaging system that shows perfusion without dye, cleared by FDA in 2021 (K203550) and 2023 (K231344). Surgeons and robotic-platform makers are its buyers, at an unpublished price. A residency director gets nothing from it, since it rates no one's technique.